MedTrace Logo

Comparison of Standard Opioid Prescription Versus Prescription Guided by Pharmacogenetic Analysis in Patients With Non-cancerous Chronic Pain.

NCT03498014 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2023-02-09

No results posted yet for this study

Summary

The investigators hypothesize that opioid prescription guided by patient pharmacogenetic profile will diminish opioid-associated undesirable effects by 50% and improve medication compliance.

Conditions

  • Non-cancerous Chronic Pain

Interventions

OTHER

Pharmacogenetic analysis allowing personalized opioid prescription

Genotypic of patient to determine optimal opioid treatment (tramadol, codeine or oxycodone)

OTHER

Standard opioid prescription

Opioid prescription made without reference to patient genetic profile (tramadol, codeine or oxycodone)

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de Nīmes

    lead OTHER

Principal Investigators

  • Jean-Christophe Boyer · CHU Nimes

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-31
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03498014 on ClinicalTrials.gov